Juan Gaspar

Interventional Cardiologist. Structural Heart Medical Education Director - Medtronic

[Davide Capodanno @DFCapodanno]

The European Valve Durability TAVI Registry highlights the long-term performance of TAVI. The incidence of moderate or severe structural valve deterioration (SVD) during long-term follow-up was relatively low, with severe SVD being even rarer than moderate SVD. SVD occurred more frequently in patients treated with older-generation intra-annular valves and in those with small-sized valves. #EuroPCR
https://t.co/TDmSHrZ8Mj

[JACC Journals @JACCJournals]

This #JACCINT analysis assessed midframe underexpansion after #TAVR with the self-expanding ACURATE neo2 valve and found it occurred in 13.9% of patients. Midframe underexpansion was associated with higher 1-year mortality, stroke, and rehospitalization. https://t.co/5mIhYsSE8R

[Davide Capodanno @DFCapodanno]

And here are finally the 5-year results of Evolut Low Risk, a trial in which the self-expanding prosthesis holds its own against surgery. A trial where, let’s remember, the average age was 74 years. For years, to the question: 'How long does a TAVI prosthesis last?' we didn’t know what to answer. Now I think we can say with certainty: 'At least 5 years.' Still too early to claim victory, but not the disaster that some predicted years ago either. #ACC25 https://t.co/CRSooELulA

[JACC Journals @JACCJournals]

Dr. @MReardon19 on the EVOLUT Low Risk trial:
📌 Low surgical risk patients with severe AS who were treated with either Evolut or surgery showed comparable rates of all-cause mortality or disabling #stroke at 5 years (15.5% Evolut and 16.4% surgery, p=0.47)

#ACC25 #JACC #SAVR

[Hooman Bakhshi @BakhshiHooman]

#ACC25 #Evolut low rish : low surgical risk pts with severe AS —> Evolut vs surgery —> comparable rates of all-cause mortality or disabling stroke at 5 years (15.5% Evolut and 16.4% surgery, p=0.47)

@Mod_Pharmacist @KimMed_ @RThachilMD @PA_Kotta @ujebubechukwu @Ibrahim_Kamel9 @DrHaloot @EspicheCarlos @drapura1 @AbdulbaqiMd @dhruva_biswas @BakhshiHooman @CandrikaDini @SSivalokanathan @AdrianaCMares @antia_md @AmitabhCPandey @thornsberryjd @Dr_ibrahimHarbi @AmroAglanMD @Yasserjamil_MD @ilanvavilinmd

[JACC Journals @JACCJournals]

Dr. @MReardon19 on the EVOLUT Low Risk trial: The results of the trial at 5 years support Evolut as a safe, effective, and durable alternative to surgery for patients with severe aortic stenosis and low surgical risk

#ACC25 #TAVR #SAVR #vhdAS #cvSurg #JACC

[Juan Manuel Telayna (h) @jmtelayna]

Chronic Total Occlusion PCI in diabetes at @CRT_meeting

[JACC Journals @JACCJournals]

ICYMI: 5-yr valve performance is significantly better after CoreValve/Evolut #TAVI compared to surgery. The development of BVD in TAVI and surgery patients was associated with worsened 5-yr clinical outcomes. https://t.co/QAX6Rnh6EY

#CRT2025 #JACC #cvSurg @aakriti_15 @MReardon19

[Dr. Gilbert Tang @GilbertTangMD]

Congrats to Howard Herrmann, @Drroxmehran @didier_tchetche and #SMART trial investigators for outstanding 2y data and outcomes #CRT2025, with excellent clinical and echo follow up! While no differences in hard endpoints (no surprise), what struck me the most is the adjudicated prosthetic valve thrombosis differences (clinical, subclinical) between #Evolut and #Sapien3 #TAVR, despite no differences (yet) in reintervention. But it reaffirms to us that BVD no matter how it’s defined is not a good thing for prosthetic valves, whether it’s TAVR or in the latest @JACCJournals paper by @StevenYakubov et al, SAVR. @MDT_StructHeart

[Gui Attizzani @GuiAttizzaniMD]

Thank you my friend ⁦@StevenYakubov⁩ for this nice podcast in which we talk about life, career, hard work and coronary access post #TAVR https://t.co/8O6QTQPzYB

[Gui Attizzani @GuiAttizzaniMD]

Great Canadian #TAVI implanters meeting last weekend in Montreal. Outstanding atmosphere led by my friends Nico Piazza and Sam Radhakrishnan…and @erichorlick showed not only his superb cardiology knowledge but also that nobody knows submarine movies like him😉
@RodrigoBagur

[Gui Attizzani @GuiAttizzaniMD]

@ShariqShamimMD Read our CANNULATE TAVR study on JACC Intv on consecutive (no selection for easier anatomies) patients for 100% coronary cannulation post TAVR with FX. You can also attend our late breaking trial presentation at London Valves for the CANNULATE TAVR EXTENDED and simultaneous paper

[Dr. Gilbert Tang @GilbertTangMD]

Just presented 1y full TRILUMINATR RCT #T-TEER TriClip system for severe TR. ⬆️WINs, KCCQ 6MWD. Congrats to all co authors and now published in @JACCJournals @hahn_rt @psorajja @HamidNadira @AbbottCardio #TCT2024 @crfheart @TCTMD

[Vinicius Esteves,MD PhD FESC @vinesteves]

Packed best global research in TAVR session during the very first hour of #TCT2024. Great discussion on coronary re-access and looking forward to CANULATE TRIAL to be presented during #PCRLV24 @GuiAttizzaniMD @OhnoTuri @ACUkaigweMD @shishem @HarringtonHVI

[Juan Gaspar @JGMD63]

Great sessions at @crfheart #TCT2024

[Gui Attizzani @GuiAttizzaniMD]

Nice discussion about coronary cannulation post-#TAVR with my brother @OhnoTuri and Prof Hyo-Soo Kim starting #ENCORE Congress in Seoul. Great to meet our friend @DFCapodanno for dinner remembering our fellowship days in Italy @FrazzettoMarco

[Gui Attizzani @GuiAttizzaniMD]

Looking forward to exciting discussions on complex #TAVI cases and a lot of learning! ⁦@UHhospitals⁩ ⁦@MDT_StructHeart⁩ ⁦@vinesteves⁩ ⁦@ACUkaigweMD⁩ ⁦@HarringtonHVI⁩ ⁦@shishem⁩ ⁦@SMPatelMD⁩ ⁦@FrazzettoMarco⁩ https://t.co/hHjdR4uG7D

[Abdelkader Almanfi, MD, FACC, FSCAI @Almanfi_Cardio]

What A Milestone for both of us!
August 21st 2024, I proctored my mentor Dr. Strickman (who taught me TAVR 10 years ago as a fellow at THI), he performed his first Evolut FX plus TAVR case, I am so glad I was able to help, I still look up to him and learn from his wisdom, courage and humility!

@Medtronic
Baylor St. Luke's Medical Center Houston Texas

[Abdelkader Almanfi, MD, FACC, FSCAI @Almanfi_Cardio]

Moderating 4 Live TAVR Evolut cases from Australia 🇦🇺, Taiwan 🇹🇼, Brazil 🇧🇷 & Argentina 🇦🇷 was a great fun alongside @AntoniousAttall
In-person discussions & debates about #TAVR latest data & best practices among implanters from different 12 nations (aside from US)
Thanks to @Medtronic for such high level academic summit.
@JGMD63

[Vinicius Esteves,MD PhD FESC @vinesteves]

Nice transmission last Friday to 🇺🇸 using the excellent MEDINBOX AIR portable system !! Great case with a lot of discussion on small annulus anatomies. @GuiAttizzaniMD @Almanfi_Cardio @medinbox @modine_thomas @didier_tchetche @msztejfman @JGMD63 @NicoGausserand